Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
NewAmsterdam Pharma Company N.V. Ordinary Shares
NAMS | US
34.68
USD1.48
4.46%
NAMS | US
About NewAmsterdam Pharma Company N.V. Ordinary Shares
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
17/04/2026
Close
34.68
Open
34.19
High
34.95
Low
33.57
NewAmsterdam Pharma Company N.V. a clinical-stage biopharmaceutical company develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib a next generation oral and low-dose cholesteryl ester transfer protein (CETP) inhibitor that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE). NewAmsterdam Pharma Company N.V. is headquartered in Naarden the Netherlands.
View LessNAMS | US
Risk
57.0
Sharpe
2.02
Luna's Score
67/100
Recommendation
Buy
Luna says (NAMS | US)
What's Working
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Strong Revenue Growth (> 10%)
Strong Sharpe Ratio (> 1.2)
What's not Working
Midcap (2B - 10B USD)
Weak Operating Margin (< 10%)
Volatility Signals
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
Risk Meter
10 days
50.2%1 month
57.0%3 months
53.0%6 months
50.8%Returns
Fundamental Ratios
PE
-
Fwd. PE
-
Price to book
4.47
Debt to equity
0.00
Debt to assets
0.00
Ent. to EBITDA
27.63
Ent. to rev.
175.59
PEG
-
Other Fundamentals
EBITDA
-208.63M
MarketCap
3.12B
MarketCap(USD)
3.12B
Div. yield
-
Op. margin
-2.31K
Erngs. growth
-
Rev. growth
32.70
Ret. on equity
-54.08
Short ratio
1.84
Short perc.
0.83
Market Sentiment (SMA and Price signals)
Short-term: Bullish (SMA10D > SMA1M)
Intermediate-term: Bearish (SMA1M < SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Range10D
4.26
Range1M
7.92
Range3M
9.23
Volumes: Market Activity
Rel. volume
0.75
Price X volume
22.08M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 27.63 | - | Expensive |
| Ent. to Revenue | 175.59 | - | Cheaper |
| PE Ratio | - | 41.03 | - |
| Price to Book | 4.47 | 15.55 | Cheaper |
| Dividend Yield | - | - | - |
| Std. Deviation (3M) | 53.04 | - | Lower Risk |
| Debt to Equity | 0.00 | -1.23 | Expensive |
| Debt to Assets | 0.00 | 0.25 | Cheaper |
| Market Cap | 3.12B | - | Par |
